Sofosbuvir/Velpatasvir/Voxilaprevir

索磷布韦/维帕他韦/伏西瑞韦

Report date: 2022/01/14 13:23:58

Base Information

Drug NameSofosbuvir/Velpatasvir/Voxilaprevir
Drug Alias NameVelpatasvir/Voxilaprevir/Sofosbuvir维帕他韦/索磷布韦/伏西瑞韦Velpatasvir/Sofosbuvir/Voxilaprevir维帕他韦/伏西瑞韦/索磷布韦Sofosbuvir/Voxilaprevir/Velpatasvir +[6] 
ClassificationSmall molecules
Mechanisms of ActionNonstructural protein 5A inhibitorsHepatitis C virus serine protease, NS3/NS4A inhibitorsHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymeraseNonstructural protein 5AHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsHepatitis C, ChronicHepatitis C
Global Approved IndicationsHepatitis C, ChronicHepatitis C
Approved Indications in ChinaHepatitis C, Chronic
Original Approved Country/TerritoryUnited States
Original Approved Date2017/07/18
Country/TerritoryCanadaUnited StatesPoland +[12] 
CombinationsYes VoxilaprevirVelpatasvirSofosbuvir
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncGilead Sciences Ireland Uc
Inactive CompaniesN/A
Active IndicationsHepatitis C, ChronicHepatitis C
Inactive IndicationsN/A

Other Information

ATC CodeJ05A
Related LinksWikipediaKEGG